RT Journal Article
SR Electronic
T1 Modeling brings additional insights into the kinetics of SARS-CoV-2 neutralizing antibody
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.13.21264693
DO 10.1101/2021.10.13.21264693
A1 Mélanie, Prague
A1 Clairon, Quentin
A1 Guedj, Jérémie
A1 Thiébaut, Rodolphe
YR 2021
UL http://medrxiv.org/content/early/2021/10/20/2021.10.13.21264693.abstract
AB Following the paper by Seow et al. published in Nature Microbiology, we reanalyzed the publicly available data using dynamical models of humoral response. The main conclusion is that, from available data, we can demonstrate that the decline of neutralizing antibodies (as measured with ID50) is biphasic, which is compatible with two types of antibody secreting cells (short lived and long lived). We found that lower bound of half life of the long-lived antibody secreting cells is 450 days. Moreover, our model predicts that the neutralizing antibody response could be more durable than suggested (up to 129 days for individuals with no requirement of supplemental oxygen and up to 175 days for others). A result which adds insight on the longevity of immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data are available as a supplementary information of this paper: https://www.nature.com/articles/s41564-020-00813-8I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used are available in the supplementary material of this paper: https://www.nature.com/articles/s41564-020-00813-8 https://www.nature.com/articles/s41564-020-00813-8